Article

AMD animal model discovered at Cleveland Clinic

Cleveland-A Cleveland Clinic research team has developed the first animal model of age-related macular degeneration (AMD), and it is expected to enable researchers to study the development and progression of AMD and conduct pre-clinical testing of new therapeutics.

Cleveland-A Cleveland Clinic research team has developed the first animal model of age-related macular degeneration (AMD), and it is expected to enable researchers to study the development and progression of AMD and conduct pre-clinical testing of new therapeutics.

The research team, led by Joe G. Hollyfield, PhD, of the institution’s Cole Eye Institute, modified specific proteins found in mouse blood so that the mouse’s immune system was forced to mount a response. This response causes the mouse to display characteristics of AMD in a short amount of time.

Specifically, Dr. Hollyfield and his team immunized mice with mouse serum albumin adducted with oxidation fragments of the long-chain fatty acid known as docosahexaenoic acid. Earlier studies by this group found that the fragments were localized in drusen from donor eye tissues and in plasma samples from patients with AMD. The immunized mice develop antibodies to the oxidation fragment, deposit complement in the outer eye wall, accumulate drusen below the retinal pigment epithelium, and show features of geographic atrophy.
 
“More than 8 million Americans are living with vision loss caused by AMD, and 250,000 new cases [are] diagnosed each year,” said Dr. Hollyfield. “The discovery of the animal model of AMD presents a significant opportunity to efficiently and effectively develop and test novel therapies to both prevent the disease and slow vision loss. Research conducted today may one day help find a cure for this progressive disease.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.